Catheter-based renal denervation in hypertension: heading for new shores
Name
nihms968193.pdf
Description
Accepted version
Size
72.82 KB
Format
Adobe PDF
Checksum (MD5)
1eebeaf015c6ffeb260641d1303a2d8d
Author(s)
Mahfoud, Felix
Edelman, Elazer R
Date Issued
January 2018
Journal
Journal of hypertension
Publisher
Ovid Technologies (Wolters Kluwer Health)
Citation
Mahfouda, Felix, Michael Böhma, and Elazer R. Edelman. “Catheter-based renal denervation in hypertension: heading for new shores.” Journal of hypertension, vol. 36, no. 1, 2018, pp. 41-42 © 2018 The Author(s)
Version
Author's final manuscript
Abstract
Autonomic imbalance, the loss of equilibrium between the sympathetic and parasympathetic nervous systems, is thought to play an important role in the pathophysiology of hypertension [1]. The activation of renal sympathetic fibers, which reside throughout the kidney and abound in the hypertensive state, leads to an increased and excessive secretion of renin, increased sodium reabsorption in the proximal tubule, and decreased renal perfusion [2]. In the not so distant past, these observations seemed to support and promote the use of surgical sympathectomy in patients with severe hypertension, including individuals with end-organ damage, and indeed was associated with significant reduction in blood pressure (BP) accompanied by reduced mortality [3]. Surgical approaches requiring major operative approach became a method of last resort and then a neglected relic of the past until catheter-based approaches promised minimally invasive targeting of renal nerves. An ablation catheter introduced through the femoral or radial artery can be advanced into the renal arteries under fluoroscopic guidance, in which radiofrequency or ultrasound energy can be deployed to ablate the sympathetic nerves [4]. Alternative approaches use chemical denervation by injection of alcohol or other neurotoxic agents in the adventitia of the renal arteries. Although minimal invasiveness was proved and early data seemed promising, unambiguous BP lowering with noninvasive renal denervation (RDN) remains elusive, especially in light of the well executed trials [5].
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1097/HJH.0000000000001614
